Presentation is loading. Please wait.

Presentation is loading. Please wait.

Will we ever see a dedicated bifurcated DES in clinical practice?

Published byCecil Gilmore Modified over 6 years ago

Similar presentations

Presentation on theme: "Will we ever see a dedicated bifurcated DES in clinical practice?"— Presentation transcript:

1 Will we ever see a dedicated bifurcated DES in clinical practice?
Aaron V. Kaplan, M.D., F.A.C.C., F.S.C.A.I  Professor of Medicine (Cardiology) Director of Research Dartmouth Medical School Cardiac Catheterization Laboratories Dartmouth-Hitchcock Medical Center

2 Aaron V. Kaplan, M.D. Conflict-of -Interests
Founder & Director: Tryton Medical Research Support: Abbot Vascular Medtronic Boston Scientific Edwards Lifesciences Practicing Interventional Cardiologist

3 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? Does this makes sense from a business perspective?

4 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? Does this makes sense from a business perspective?

5 Defining the Clinical Need
‘True’ Bifurcation Lesions involving large side branches Medina (1.1.1, 0.1.1, 1.0.1) Large Side Branch Large Myocardium at risk What about Provisional Stenting? Nordic 1 & BBC1 Population Smaller side branches Only treated ~1/3 of time

6 Provisional Stenting Small side branch without apparent disease

7 Provisional Stenting? Disease in BOTH main vessel & side branch large

8 Defining the Clinical Need
‘True’ Bifurcation Lesions involving large side branches Medina (1.1.1, 0.1.1, 1.0.1) Large Side Branch Large Myocardium at risk Nordic I & BBC1 Smaller side branches Only treated ~1/3 of time

9 Nordic I 1 Stent is all you need?

10 Nordic 1 MV (Provisional) MV + SB Treatment Strategy
POBA if <TIMI 3 Stent if TIMI 0 after POBA SB treatment 32% of pts Treatment Strategy Culotte, ‘T’ or Crush Final Kissing Inflations Final Kiss in 74% of pts

11 Nordic 1 MV (Provisional) MV + SB Treatment Strategy Results
POBA if <TIMI 3 Stent if TIMI 0 after POBA SB treatment 32% of pts Results Procedural CPK: 8%+ 6 mos: 2.9% *Mace definition excludes procedural MI +p = 0.01 Treatment Strategy Culotte, ‘T’ or Crush Final Kissing Inflations Final Kiss in 74% of pts Results Procedural CPK: 18%+ 6 mos = 3.4%

12 Nordic 1 Implies SB with small territories
Interventionist comfortable NOT treating Clinically Silent

13 Defining the Clinical Need
‘True’ Bifurcation Lesions involving large side branches Medina (1.1.1, 0.1.1, 1.0.1) Large Side Branch Large Myocardium at risk

14 Dedicated DES in our Future: Need to answer the following Questions
What is the unmet clinical need? ‘True’ Bifurcation Lesion SB perfusing large myocardial territories Physician is committed to treatment What are the regulatory barriers? What are the business realities?

15 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? Does this makes sense from a business perspective?

16 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? What are Clinicians looking for? What are Regulators (FDA) looking for? Does this makes sense* from a business perspective?

17 What are operators looking for
What are operators looking for? The ability to easily/reliably stent the lesion Durable Stent Solution Moving beyond POBA Procedure Ease-of-Use 6 Fr Guide Single Wire Reduce transient closure Reproducible results Long Term Results DES Defined/reduced restenosis

18 What are operators looking for
What are operators looking for? The ability to easily/reliably stent the lesion Baseline Post Procedure Procedural Success Diag Stent: Tryton LAD Stent: Cypher 6 Month F/U No Restenosis High Grade Lesion Mid LAD-Diag Medina (1,1,1) 18

19 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? What are Clinicians looking for? What are Regulators (FDA) looking for? Does this makes sense* from a business perspective?

20 Need for DES Drives Regulatory Pathway
Balloon Expandable Self-Expanding Tryton Balloon Delivery System ‘Hybrid’ BMS Tryton + DES Main Vessel Stent Main Vessel Side Branch Cappella Nitinol stent Sheathed Balloon Delivery System ‘Hybrid’ BMS Cappella + DES Main Vessel Stent Abbott BSC Medtronic, Cordis TriReme Minvasys (EU Only) Launching Paciltaxel DES Devax IDE Approved Stentys Self expanding stent in STEMI Developing Paclitaxel DES DES Required

21 Abbott Vascular/GDT ML FrontierTM Demonstrates DES required for dedicated Main Vessel-Bifurcation Stents Stent Characteristics: BMS (18 mm) Delivery System (7Fr) Single Tip Delivery to avoid wire wrap Simultaneous inflation Provisional Dynamic Frontier Stent Registry N = 105 Angiographic Follow-up 180 days BAR (Combined) = 44.8% MB (in seg) = 29.9%, SB = 29.1% Lefèvre T, et al. J Am Coll Cardiol 2005;46:592–8

22 TrytonFirst-In-Man Results Support Hybrid (BMS Tryton + DES) Strategy
Superb procedural results, ease-of-use validated 6F guide usage 100% simultaneous kiss Great angiographic results DES-like late loss results in both branches Main Vessel (Proximal): ± 0.43 mm Main Vessel (Distal): ± 0.31 mm Side Branch: 0.17 ± 0.35 mm 9-month clinical results Low Target Lesion Revascularization (3%) No (0%) side branch failures Tryton Side Branch (BMS) Main Vessel Stent (DES) Onuma et al, Eurointerv 2008;3: 22

23 TrytonFirst-In-Man Results Support Hybrid (BMS Tryton + DES) Strategy
Cumulative incidence (%) Prox main 0.25 ± 0.43 Distal main 0.00 ± 0.31 Side 0.17 ± 0.35 Onuma et al, Eurointerv 2008;3: LLL (mm) 23 23

24 Regulatory Perspective
Reasonable Safety and Effectiveness Safety driven by clinical end point Main Vessel Stent DES: Increases regulatory concerns Drug:Drug Interactions Side Branch (BMS) + Main Vessel (DES) Stent:Stent Interactions

25 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? What are the operators looking for? What are the regulators (FDA) looking for? Does this makes sense* from a business perspective? *Makes sense = Makes $ for investors

26 Dedicated Bifurcation Stent? Need to answer the following Questions
What is the unmet clinical need? Is the clinical need being addressed? What are the operators looking for? What are the regulators (FDA) looking for? Does this makes sense* from a business perspective? Is the need (market) large enough? Investment (time & $) is required? *Makes sense = Makes $ for investors

27 Is the need (market) large enough? ~20% of all PCI’s
Kukreja N, Onuma Y,van Domburg R, Serruys P. ACC ‘08 Bifurcations Treated as % of PCI's Rotterdam (cSearch, tSearch & xSearch) Series “All Comers” Studies % Patients % Lesions Leaders Trial1,2 29.1% 21.6% Nobori 23 17.5% 16.9% xSearch4 22.2% N/A Average 22.9% 19.3% 1. Windecker et al. Lancet 2008; 372: 1163–73 2. Wykrzykowska, EuroPCR ’09 3. Danzi, EuroPCR ‘09 4. Serruys, ACC ‘08

28 Investment (Time/$) is required? Study Size Drives the equation
Main Vessel DES Large Company ABT, BSC, Cordis/JnJ, MDT Canabalizes ‘Workhorse’ DES Sales ‘Start-up’ Company 1st in class + unapporved Drug/Polymer Side Branch BMS + Approved DES More ‘Doable’

29 Are Large RCT Feasible? Resources & Time
BBC-1 N=500 Centers = 21 Recruitment = 3 years Hilldick-Smith TCT ‘08

30 Yes! A Stent based solution for bifurcation lesions is in our future!
Conclusions: What is the unmet clinical need? ‘True’ Bifurcations involving large side branches Is the clinical need being addressed? Early data promising RCT Trials required to address safety & efficacy Does this makes from a business perspective? Large poorly addressed need (Large market opportunity) Accessible with manageable IDE Trial (RCT <750 patients) Yes! A Stent based solution for bifurcation lesions is in our future!

31 Thank you

Download ppt "Will we ever see a dedicated bifurcated DES in clinical practice?"

Similar presentations

J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.

J BERLAND, SAINT-HILAIRE, ROUEN ST+: Stenting après pré-dilataion et ouverture de maille.
A multicenter, randomized, prospective DKCRUSH-III study

A multicenter, randomized, prospective DKCRUSH-III study
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,

Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.

Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N

BIFURCATION LESIONS Dr. Tahsin.N
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.

Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I

29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Bifurcation Stenting: A primer

Bifurcation Stenting: A primer
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.

FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.

TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.

Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.

Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.

J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.

Dedicated Bifurcation Stent Technology: Implications for Everyday Practice Jens Flensted Lassen MD, PH.D., FESC The Heart Centre, Rigshospitalet University.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.

Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The FRONTIER Stent Registry: Safety and Feasibility.

Date of download: 7/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: The FRONTIER Stent Registry: Safety and Feasibility.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.

Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Durable Polymer DES: 5 Year Outcomes RESOLUTE Update Sigmund Silber, MD FESC, FACC, FAHA Heart Center at the Isar Munich, Germany On Behalf of the RESOLUTE.

Similar presentations

Ads by Google